Search Results
Nov 06, 2025, 08:00 ET Cure by Deerfield Middle East Health Accelerator Selects 15 Startups for Inaugural Cohort
that brings single-visit detection into the neighborhood clinic. Pinecone Therapeutics (USA): Gene therapy program targeting propionic acidemia (PA), a rare metabolic disorder. Valeo Health (UAE):
More news about: Cure
Nov 06, 2025, 08:00 ET Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
and function in six- to 14-year-old participants with Duchenne who have been previously treated with gene therapy. FOX participants are on average over 10 years old and four years out from receiving gene therapy. Initial results from the FOX study support that sevasemten 10 mg has the potential to reduce
More news about: Edgewise Therapeutics
Nov 06, 2025, 07:27 ET MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
(NCT07181837) represents the first clinical evaluation of a gene therapy for AS. Supported by the Foundation for Angelman Syndrome Therapeutics (FAST) and AS2Bio, MavriX Bio developed MVX-220 to restore functional expression of the UBE3A gene in neurons using targeted AAV delivery to the central
More news about: AS2Bio
Nov 06, 2025, 07:05 ET REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; PDUFA date February 8, 2026 Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy for chronic retinal disease
More news about: REGENXBIO Inc.
Nov 06, 2025, 07:00 ET SkylineDx Wins 2025 BioTech Breakthrough Award for "Diagnostics Company of the Year"
decisions across all stages of melanoma and is available commercially in the U.S. and Europe. The Merlin GP-GEP Test combines clinicopathologic factors with gene expression analysis to assess a patient's risk of melanoma metastases. SkylineDx recently published a landmark study in
More news about: SkylineDx
Nov 06, 2025, 05:04 ET Proxima Clinical Research Acquired, Names Industry Veteran Eric Ross as new CEO to Drive Growth in Houston MedTech Hub
MedTech right here in Texas." Howell's ownership also extends to HGI Clinical, a CRO dedicated to early-phase oncology and cell and gene therapy drug development. This synergy between Proxima and HGI Clinical is expected to create a robust platform for accelerated medical advancements.
More news about: ProximaCRO
Nov 06, 2025, 04:00 ET Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
proteins. Together, the scientists propose a new model of gene regulation in which cells use electromagnetic forces to bring DNA control sequences to the surface, where they cluster into "islands" of gene activity. These structures, which were previously invisible, appear to be a fundamental
More news about: Nucleome Therapeutics
Nov 06, 2025, 02:11 ET Kanazawa University research: Protein droplets in the nucleus guard against cancer
Figure 2. CHD1 condensability is essential for gene regulation and tumor suppression. CHD1's ability to form condensates is required for its localization to gene promoters (A). In prostate cancer cells carrying the CHD1 E1321fs mutation lacking the C-terminal
More news about: Kanazawa University
Nov 05, 2025, 19:42 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
advances in gene-editing technologies, it is now possible to therapeutically modulate APOC3 expression at the genetic level to lower TG levels — offering a potential curative strategy for chylomicronemia and hypertriglyceridemia. CS-121, Correctseq's first in vivo gene-editing
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 19:00 ET The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
advances in gene-editing technologies, it is now possible to therapeutically modulate APOC3 expression at the genetic level to lower TG levels — offering a potential curative strategy for chylomicronemia and hypertriglyceridemia. CS-121, Correctseq's first in vivo gene-editing
More news about: CorrectSequence Therapeutics
Nov 05, 2025, 16:05 ET Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
potency against activating FGFR2 gene alterations and resistance mutations. The SURF201 study continues to enroll and dose adults with unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma (ICC) and other advanced solid tumors with activating FGFR2 gene alterations.
More news about: Tyra Biosciences
Nov 05, 2025, 08:00 ET IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025
Showcased end-to-end, customized manufacturing capabilities covering vaccines, gene and immune therapeutics Strengthening global CDMO strategy through strategic
More news about: SK bioscience
Nov 05, 2025, 07:07 ET Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Umoja's VivoVec™ in vivo gene delivery technology empowers a patient's own immune system to fight disease. Enabling its core technology is the Company's state- of-the-art lentiviral
More news about: Nona Biosciences
Nov 05, 2025, 07:00 ET Insmed To Present at November and December 2025 Investor Conferences
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater,
More news about: Insmed Incorporated
Nov 04, 2025, 16:30 ET Corteva Raises Full-Year Guidance on Strong Third Quarter and Year-To-Date 2025 Results
differentiated technology solutions in crop protection, including biologicals, and "SpinCo," dedicated to advanced genetics and emerging technologies including gene editing, hybrid wheat, and biofuels. The transaction is expected to be completed in the second half of 2026, subject to customary approvals.
More news about: Corteva Agriscience
Nov 04, 2025, 16:05 ET Cryoport Reports Third Quarter 2025 Financial Results
revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences
More news about: Cryoport, Inc.
Nov 04, 2025, 14:00 ET CIR-0602K Demonstrates Synergistic Metabolic Benefit with Tirzepatide: New Data Presented at ObesityWeek 2025
4, 2025Time: 2:15 PM ETLocation: Georgia World Congress Center, Room A411-A412 More detailed gene expression data will also be presented at an attended poster session, Cooperative Interactions Found in Combination of MPC Insulin Sensitizer and
More news about: Cirius Therapeutics
Nov 04, 2025, 12:30 ET Loma Linda University Health awarded $9 million from the California Institute for Regenerative Medicine
Funds will support cell, gene, and regenerative medicine therapy LOMA LINDA, Calif., Nov. 4, 2025 /PRNewswire/ -- The
More news about: Loma Linda University Health
Nov 04, 2025, 12:00 ET Mickey Thompson Revives a Legend: Baja Belted™ II Debuts at SEMA 2025
Wheels offers performance, racing and off-road tires and wheels. Headquartered in Stow, Ohio, USA, the company was founded in 1963 by Mickey Thompson and Gene McMannis. Today, Mickey Thompson Tires & Wheels markets their products globally, empowering automotive enthusiasts, competitive racers, and weekend
More news about: The Goodyear Tire & Rubber Company
Nov 04, 2025, 12:00 ET Mickey Thompson Introduces the Street Comp™ GHT: A Bold Step Forward in Street Performance
Wheels offers performance, racing and off-road tires and wheels. Headquartered in Stow, Ohio, USA, the company was founded in 1963 by Mickey Thompson and Gene McMannis. Today, Mickey Thompson Tires & Wheels markets their products globally, empowering automotive enthusiasts, competitive racers, and weekend
More news about: The Goodyear Tire & Rubber Company
Nov 04, 2025, 12:00 ET A Legend Reborn: Mickey Thompson Unveils MT Classic Forged Wheels
Wheels offers performance, racing and off-road tires and wheels. Headquartered in Stow, Ohio, USA, the company was founded in 1963 by Mickey Thompson and Gene McMannis. Today, Mickey Thompson Tires & Wheels markets their products globally, empowering automotive enthusiasts, competitive racers, and weekend
More news about: The Goodyear Tire & Rubber Company
Nov 04, 2025, 11:00 ET Amyris Launches New Brand and Website to align with Strategic Growth Pillars.
sustainable supply chains, and deliver product differentiation and competitive advantage in the market. "Amyris is unique because of our ability to go from gene discovery and strain engineering to scaled manufacturing with world-class science, knowledge, and experience," Fortmann said. "One of our greatest differentiators
More news about: Amyris, Inc.
Nov 04, 2025, 10:17 ET PPMD Provides $400,000 in Funding to MyoGene Bio Through PPMD Venture Pathways Program to Support Development of Gene Editing Platform
a change in the DMD gene that codes for the dystrophin protein. Gene editing is a strategy to make permanent alterations to an individual's DNA to restore function of the gene. MyoGene's strategy, known as MyoDys45-55, utilizes gene editing technology to edit
More news about: Parent Project Muscular Dystrophy (PPMD)
Nov 04, 2025, 08:30 ET Ensuring compliance with animal-free raw materials in CGT, Upcoming Webinar Hosted by Xtalks
TORONTO, Nov. 4, 2025 /PRNewswire/ -- The production of cell and gene therapies faces stringent regulatory requirements that demand the use of high-quality, animal-free raw materials to ensure patient safety and product
More news about: Xtalks
Nov 04, 2025, 07:30 ET Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential
More news about: Actinium Pharmaceuticals, Inc.